Ole Haagen Nielsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9389784/publications.pdf

Version: 2024-02-01

241	14,339	22548 61	29333 108
papers	citations	h-index	g-index

253	253	253	17665
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 74-87.e3.	2.4	57
2	Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets. International Journal of Biological Sciences, 2022, 18, 1813-1828.	2.6	5
3	Tuft Cells and Their Role in Intestinal Diseases. Frontiers in Immunology, 2022, 13, 822867.	2.2	42
4	Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. Stem Cells, 2022, 40, 447-457.	1.4	6
5	Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends in Pharmacological Sciences, 2022, 43, 424-436.	4.0	10
6	Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer. Microorganisms, 2022, 10, 1371.	1.6	19
7	Identification, isolation and analysis of human gut-associated lymphoid tissues. Nature Protocols, 2021, 16, 2051-2067.	5.5	28
8	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
9	Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
10	IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine, 2021, 71, 103551.	2.7	16
11	Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2021, 116, 243-253.	0.2	17
12	Telomere dysfunction activates YAP1 to drive tissue inflammation. Nature Communications, 2020, 11, 4766.	5.8	42
13	Mucosal vitamin D signaling in inflammatory bowel disease. Autoimmunity Reviews, 2020, 19, 102672.	2.5	34
14	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine, 2020, 20, 100271.	3.2	23
15	Immune Profiling of Human Gut-Associated Lymphoid Tissue Identifies a Role for Isolated Lymphoid Follicles in Priming of Region-Specific Immunity. Immunity, 2020, 52, 557-570.e6.	6.6	90
16	SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Science Signaling, 2020, 13, .	1.6	34
17	A fully defined 3D matrix for ex vivo expansion of human colonic organoids from biopsy tissue. Biomaterials, 2020, 262, 120248.	5.7	16
18	Metabonomics in Gastroenterology and Hepatology. International Journal of Molecular Sciences, 2019, 20, 3638.	1.8	4

#	Article	IF	Citations
19	Systematic review with metaâ€analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 1146-1158.	1.9	69
20	Managing vitamin D deficiency in inflammatory bowel disease. Frontline Gastroenterology, 2019, 10, 394-400.	0.9	42
21	Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy. Stem Cell Research and Therapy, 2019, 10, 148.	2.4	11
22	Methotrexate for inflammatory bowel disease: time for reconsideration. Expert Review of Gastroenterology and Hepatology, 2019, 13, 407-409.	1.4	6
23	Biosimilars for Management of Crohn Disease. Annals of Internal Medicine, 2019, 170, 129.	2.0	3
24	Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 742-752.	0.6	67
25	YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM Remodeling to Tissue Regeneration. Cell Stem Cell, 2018, 22, 35-49.e7.	5.2	447
26	Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies. Nature Communications, 2018, 9, 1661.	5.8	78
27	Intestinal barrier integrity and inflammatory bowel disease: Stem cellâ€based approaches to regenerate the barrier. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 923-935.	1.3	48
28	Inflammatory bowel disease with primary sclerosing cholangitis: A Danish populationâ€based cohort study 1977â€2011. Liver International, 2018, 38, 532-541.	1.9	58
29	Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. BMJ Open, 2018, 8, e018166.	0.8	15
30	COX-2â€“PGE2 Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis. EBioMedicine, 2018, 36, 497-507.	2.7	63
31	Targeting JAK-STAT signal transduction in IBD. , 2018, 192, 100-111.		69
32	Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. Nutrients, 2018, 10, 82.	1.7	43
33	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterology, 2018, 5, e000208.	1.1	29
34	Regulation of Laminin Î³2 Expression by CDX2 in Colonic Epithelial Cells Is Impaired During Active Inflammation. Journal of Cellular Biochemistry, 2017, 118, 298-307.	1.2	8
35	Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. EMBO Molecular Medicine, 2017, 9, 558-570.	3.3	69
36	Modulation of Gut Microbiota in Pathological States. Engineering, 2017, 3, 83-89.	3.2	26

#	Article	IF	Citations
37	Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease. Trends in Molecular Medicine, 2017, 23, 362-374.	3.5	57
38	Novel Targeted Therapies for Inflammatory Bowel Disease. Trends in Pharmacological Sciences, 2017, 38, 127-142.	4.0	142
39	An open prospective study evaluating efficacy and safety of a new medical device for rectal application of activated carbon in the treatment of chronic, uncomplicated perianal fistulas. International Journal of Colorectal Disease, 2017, 32, 509-512.	1.0	3
40	Anti-Inflammatory Effects of Smac-Mimetic BV6 on Immune Cells in Crohn's Disease. Gastroenterology, 2017, 152, S764.	0.6	0
41	Relation between NOD2 genotype and changes in innate signaling in Crohnâ€™s disease on mRNA and miRNA levels. Npj Genomic Medicine, 2017, 2, 3.	1.7	7
42	Inflammatory Bowel Disease and Small Bowel Cancer Risk,ÂClinical Characteristics, and Histopathology: AÂPopulation-Based Study. Clinical Gastroenterology and Hepatology, 2017, 15, 1900-1907.e2.	2.4	59
43	How genetic testing can lead to targeted management of XIAP deficiencyâ€“related inflammatory bowel disease. Genetics in Medicine, 2017, 19, 133-143.	1.1	26
44	Impact of feedback and monitoring on colonoscopy withdrawal times and polyp detection rates. BMJ Open Gastroenterology, 2017, 4, e000142.	1.1	15
45	Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. International Journal of Molecular Sciences, 2017, 18, 2046.	1.8	20
46	A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. Nutrients, 2017, 9, 499.	1.7	24
47	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Medicine, 2017, 15, 184.	2.3	34
48	Iron replacement therapy. Current Opinion in Gastroenterology, 2016, 32, 128-135.	1.0	13
49	Objective Quantification of Immune Cell Infiltrates and Epidermal Proliferation in Psoriatic Skin: A Comparison of Digital Image Analysis and Manual Counting. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 453-458.	0.6	10
50	Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-Î± Independent Crohn Disease. Medicine (United States), 2016, 95, e3417.	0.4	19
51	Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994â€“2010: a population-based study. Journal of Gastroenterology, 2016, 51, 891-899.	2.3	29
52	Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. , 2016, 159, 110-119.		77
53	Will novel oral formulations change the management of inflammatory bowel disease?. Expert Opinion on Investigational Drugs, 2016, 25, 709-718.	1.9	23
54	Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. Journal of Gastroenterology, 2016, 51, 796-807.	2.3	11

#	Article	IF	Citations
55	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2016, 55, 257-274.	1.6	42
56	Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease. Medicine (United States), 2015, 94, e963.	0.4	67
57	Alpha-1 Antitrypsin and Granulocyte Colony-stimulating Factor as Serum Biomarkers of Disease Severity in Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 1077-1088.	0.9	17
58	Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease. Clinical and Translational Gastroenterology, 2015, 6, e122.	1.3	17
59	IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. Journal of Gastroenterology, 2015, 50, 180-190.	2.3	61
60	Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. Clinical and Experimental Immunology, 2015, 179, 426-434.	1.1	18
61	Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. American Journal of Physiology - Renal Physiology, 2015, 308, G92-G99.	1.6	18
62	ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy, 2015, 11, 585-594.	4.3	100
63	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Alimentary Pharmacology and Therapeutics, 2015, 42, 71-83.	1.9	218
64	Integrative Transcriptomic and Metabonomic Molecular Profiling of Colonic Mucosal Biopsies Indicates a Unique Molecular Phenotype for Ulcerative Colitis. Journal of Proteome Research, 2015, 14, 479-490.	1.8	13
65	The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 177-189.	1.4	27
66	Metabonomics of human fecal extracts characterize ulcerative colitis, Crohnâ€™s disease and healthy individuals. Metabolomics, 2015, 11, 122-133.	1.4	208
67	New Strategies for Treatment of Inflammatory Bowel Disease. Frontiers in Medicine, 2014, 1, 3.	1.2	47
68	Identification of TNF-Â-Responsive Promoters and Enhancers in the Intestinal Epithelial Cell Model Caco-2. DNA Research, 2014, 21, 569-583.	1.5	12
69	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. Europace, 2014, 16, 477-484.	0.7	107
70	Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. Alimentary Pharmacology and Therapeutics, 2014, 39, 743-744.	1.9	6
71	IBD medications during pregnancy and lactation. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 116-127.	8.2	67
72	Assessment of the validity of a multigene analysis in the diagnostics of inflammatory bowel disease. Journal of Internal Medicine, 2014, 275, 484-493.	2.7	18

#	Article	IF	Citations
73	Proximal collagenous gastroenteritides: Clinical management. A systematic review. Annals of Medicine, 2014, 46, 311-317.	1.5	23
74	Prognosis After First-Time Myocardial Infarction in Patients With Inflammatory Bowel Disease According to Disease Activity. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 857-862.	0.9	18
75	Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure. Circulation: Heart Failure, 2014, 7, 717-722.	1.6	63
76	Transcriptional Analysis of Left-sided Colitis, Pancolitis, and Ulcerative Colitis-associated Dysplasia. Inflammatory Bowel Diseases, 2014, 20, 2340-2352.	0.9	27
77	Integration of transcriptomics and metabonomics: improving diagnostics, biomarker identification and phenotyping in ulcerative colitis. Metabolomics, 2014, 10, 280-290.	1.4	24
78	Involvement of CDX2 in the cross talk between TNF-Î± and Wnt signaling pathway in the colon cancer cell line Caco-2. Carcinogenesis, 2014, 35, 1185-1192.	1.3	31
79	Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends in Molecular Medicine, 2014, 20, 652-665.	3.5	96
80	Inflammatory pathways of importance for management of inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 64.	1.4	113
81	Collagenous sprue: a coeliac disease look-alike with different treatment strategy. BMJ Case Reports, 2014, 2014, bcr2014203721-bcr2014203721.	0.2	34
82	Which Biological Agents Are Most Appropriate for Ulcerative Colitis?. Annals of Internal Medicine, 2014, 160, 733.	2.0	6
83	ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis. Journal of Molecular Medicine, 2013, 91, 839-849.	1.7	20
84	Recent Advances Using Immunomodulators for Inflammatory Bowel Disease. Journal of Clinical Pharmacology, 2013, 53, 575-588.	1.0	37
85	Muramyl dipeptide responsive pathways in Crohnâ€™s disease: from NOD2 and beyond. Cellular and Molecular Life Sciences, 2013, 70, 3391-3404.	2.4	26
86	Safety of TNF-Î± inhibitors during IBD pregnancy: a systematic review. BMC Medicine, 2013, 11, 174.	2.3	117
87	Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease. New England Journal of Medicine, 2013, 369, 754-762.	13.9	282
88	Transplantation of Expanded Fetal Intestinal Progenitors Contributes to Colon Regeneration after Injury. Cell Stem Cell, 2013, 13, 734-744.	5.2	329
89	Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacological Research, 2013, 76, 1-8.	3.1	258
90	The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method. Alimentary Pharmacology and Therapeutics, 2013, 38, 1109-1118.	1.9	23

#	Article	IF	Citations
91	Can TNF inhibitors be administered during the third trimester?. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 130-131.	8.2	9
92	Mucosal Healing in Ulcerative Colitis. Advances in Clinical Chemistry, 2013, 59, 101-123.	1.8	25
93	Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease. New England Journal of Medicine, 2013, 369, 2561-2562.	13.9	13
94	Caspase 14 does not influence intestinal epithelial cell differentiation. Cell Death and Differentiation, 2013, 20, 524-524.	5.0	3
95	Tissue-regenerating functions of coagulation factorÂXIII. Journal of Thrombosis and Haemostasis, 2013, 11, 806-816.	1.9	28
96	Use of thiopurines in inflammatory bowel disease. World Journal of Gastroenterology, 2013, 19, 1040.	1.4	32
97	A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohnâ€™s Disease. PLoS ONE, 2013, 8, e60094.	1.1	117
98	miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World Journal of Gastroenterology, 2013, 19, 4289.	1.4	81
99	Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death â€“ A Danish Nationwide Cohort Study. PLoS ONE, 2013, 8, e56944.	1.1	182
100	Cytokines and Organ Failure in Acute Pancreatitis. Pancreas, 2012, 41, 271-277.	0.5	114
101	MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics. World Journal of Gastroenterology, 2012, 18, 4629.	1.4	88
102	TNF-Î±-induced down-regulation of CDX2 suppresses MEP1A expression in colitis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 843-851.	1.8	43
103	Biological Treatment of Crohnâ€™s Disease. Digestive Diseases, 2012, 30, 121-133.	0.8	9
104	pcaGoPromoter - An R Package for Biological and Regulatory Interpretation of Principal Components in Genome-Wide Gene Expression Data. PLoS ONE, 2012, 7, e32394.	1.1	25
105	Same review quality in open versus blinded peer review in "Ugeskrift for LÃ¦ger". Danish Medical Journal, 2012, 59, A4479.	0.5	7
106	Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 395-404.	8.2	73
107	Overexpression of Receptors for Insulin and Epidermal Growth Factor in Dysplastic Inflamed Colonic Mucosa Correlates With Increased Cancer Risk in Patients With Ulcerative Colitis. Gastroenterology, 2011, 140, S-350.	0.6	0
108	MAP kinases in inflammatory bowel disease. Clinica Chimica Acta, 2011, 412, 513-520.	0.5	138

#	Article	IF	Citations
109	The role of CDX2 in intestinal homeostasis and inflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 283-289.	1.8	68
110	ExÂvivo intestinal adhesion of Escherichia coli LF82 in Crohnâ€™s disease. Microbial Pathogenesis, 2011, 51, 426-431.	1.3	14
111	Quantification of specific E. coli in gut mucosa from Crohn's disease patients. Journal of Microbiological Methods, 2011, 86, 111-114.	0.7	8
112	Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine, 2011, 270, 15-28.	2.7	34
113	Alpha-Defensin DEFA1A3 Gene Copy Number Elevation in Danish Crohnâ€™s Disease Patients. Digestive Diseases and Sciences, 2011, 56, 3517-3524.	1.1	21
114	Are NOD2 polymorphisms linked to a specific disease endophenotype of CrohnÊ¼s disease?. Inflammatory Bowel Diseases, 2011, 17, 2392-2401.	0.9	7
115	A role for interleukin-33 in TH2-polarized intestinal inflammation?. Mucosal Immunology, 2011, 4, 496-502.	2.7	38
116	Involvement of cellular inhibitor of apoptosis protein 2 (cIAP2) in intestinal wound healing. FASEB Journal, 2011, 25, 121.1.	0.2	0
117	Genome-wide gene expression analysis of mucosal colonic biopsies and isolated colonocytes suggests a continuous inflammatory state in the lamina propria of patients with quiescent ulcerative colitis. Inflammatory Bowel Diseases, 2010, 16, 999-1007.	0.9	41
118	IL-33 is upregulated in colonocytes of ulcerative colitis. Immunology Letters, 2010, 128, 80-85.	1.1	139
119	The safety of osmotically acting cathartics in colonic cleansing. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 557-564.	8.2	55
120	Metabonomics in Ulcerative Colitis: Diagnostics, Biomarker Identification, And Insight into the Pathophysiology. Journal of Proteome Research, 2010, 9, 954-962.	1.8	141
121	Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management. Annals of Medicine, 2010, 42, 97-114.	1.5	249
122	Influence of Smoking on Colonic Gene Expression Profile in Crohn's Disease. PLoS ONE, 2009, 4, e6210.	1.1	30
123	Evidence for Impaired CARD15 Signalling in Crohn's Disease without Disease Linked Variants. PLoS ONE, 2009, 4, e7794.	1.1	17
124	Diagnosis and management of fistulizing Crohn's disease. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 92-106.	1.7	104
125	Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflammatory Bowel Diseases, 2009, 15, 1032-1038.	0.9	103
126	Mitogen activated protein kinases: a role in inflammatory bowel disease?. Clinical and Experimental Immunology, 2009, 158, 272-280.	1.1	147

#	Article	IF	Citations
127	Epithelial apoptosis: Cause or consequence of ulcerative colitis?. Scandinavian Journal of Gastroenterology, 2009, 44, 1429-1434.	0.6	26
128	W1568 Inhibitor of Apoptosis Protein-2 (cIAP2) Is Important for Colonic Epithelial Wound Healing. Gastroenterology, 2009, 136, A-693.	0.6	1
129	Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, 1623-1629.	0.9	18
130	Technology Insight: metabonomics in gastroenterologyâ€"basic principles and potential clinical applications. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 332-343.	1.7	32
131	Non-IBD and noninfectious colitis. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 28-39.	1.7	61
132	Expression of the genesdualoxidase2,lipocalin 2andregenerating islet-derived 1 alphain Crohn's disease. Scandinavian Journal of Gastroenterology, 2007, 42, 454-463.	0.6	39
133	CARD15 Single Nucleotide Polymorphisms 8, 12 and 13 Are Not Increased in Ethnic Danes with Sarcoidosis. Respiration, 2007, 74, 76-79.	1.2	27
134	Treatment response and colonic gene expression in patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2007, 42, 834-840.	0.6	9
135	Drug Insight: aminosalicylates for the treatment of IBD. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 160-170.	1.7	122
136	Clinical phenotype and gene expression profile in Crohn's disease. American Journal of Physiology - Renal Physiology, 2007, 292, G298-G304.	1.6	16
137	CARD15 Status and Familial Predisposition for Crohn's Disease and Colonic Gene Expression. Digestive Diseases and Sciences, 2007, 52, 1783-1789.	1.1	10
138	Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 1031-1038.	1.4	20
139	Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: A comparative study of inflammatory bowel disease and colonic neoplasms. Scandinavian Journal of Gastroenterology, 2006, 41, 318-325.	0.6	19
140	Interleukin-4 and 13 Induce the Expression and Release of Monocyte Chemoattractant Protein 1, Interleukin-6 and Stem Cell Factor From Human Detrusor Smooth Muscle Cells: Synergy With Interleukin-1Î² and Tumor Necrosis Factor-Î±. Journal of Urology, 2006, 175, 760-765.	0.2	25
141	Onercept for Moderate-to-Severe Crohnâ€™s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2006, 4, 888-893.	2.4	65
142	Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. Apmis, 2006, 114, 508-517.	0.9	26
143	Favourable effect of TNF-Î± inhibitor (infliximab) on Blau syndrome in monozygotic twins with ade novoCARD15mutation. Apmis, 2006, 114, 912-919.	0.9	106
144	Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1? generation. Clinical and Experimental Immunology, 2006, 147, 061127015327006-???.	1.1	832

#	Article	IF	Citations
145	Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. Alimentary Pharmacology and Therapeutics, 2006, 23, 27-33.	1.9	29
146	Continuous cytokine exposure of colonic epithelial cells induces DNA damage. European Journal of Gastroenterology and Hepatology, 2005, 17, 363-369.	0.8	23
147	Insulin-like Growth Factor Binding Protein 3 in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2005, 50, 780-784.	1.1	7
148	Microarrays and Crohn's disease: Collecting reliable information. Scandinavian Journal of Gastroenterology, 2005, 40, 369-377.	0.6	9
149	Infliximab. European Journal of Gastroenterology and Hepatology, 2004, 16, 639-641.	0.8	48
150	Comparative Studies of Superoxide Production by Microbial Wall Product-Primed Neutrophils in Ulcerative Colitis. Digestive Diseases and Sciences, 2004, 49, 878-882.	1.1	4
151	Spontaneous aggregation of leukocytes in active ulcerative colitis might be ICAM-1 dependent. Inflammation Research, 2004, 53, 458-461.	1.6	7
152	Alcohol modulates circulating levels of interleukinâ€6 and monocyte chemoattractant proteinâ€1 in chronic pancreatitis. Scandinavian Journal of Gastroenterology, 2004, 39, 277-282.	0.6	16
153	Continuous interferon-? or tumor necrosis factor-? exposure of enterocytes attenuates cell death responses. Cytokine, 2004, 27, 113-119.	1.4	12
154	Microscopic colitis: a missed diagnosis?. Lancet, The, 2004, 364, 2055-2057.	6.3	55
155	Expression of ICAM-1 in colon epithelial cells: an ultrastructural study performed on in vivo and in vitro models. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 774-781.	1.4	13
156	Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor. Scandinavian Journal of Gastroenterology, 2003, 38, 141-146.	0.6	22
157	Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 2003, 38, 180-185.	0.6	222
158	Ca2+ response in neutrophils after exposure to bacterial N-formyl-methionyl-leucyl-phenylalanine. European Journal of Gastroenterology and Hepatology, 2003, 15, 267-273.	0.8	5
159	Simple and efficient method for isolation and cultivation of endoscopically obtained human colonocytes. American Journal of Physiology - Renal Physiology, 2003, 285, G1122-G1128.	1.6	29
160	Subcellular Localization of Intercellular Adhesion Molecule-1 in Colonic Mucosa in Ulcerative Colitis. Ultrastructural Pathology, 2002, 26, 113-121.	0.4	20
161	Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). European Journal of Gastroenterology and Hepatology, 2002, 14, 243-248.	0.8	15
162	Expression of 5-lipoxygenase mRNA is unchanged in the colon of patients with active inflammatory bowel disease. Inflammation Research, 2002, 51, 423-426.	1.6	7

#	Article	IF	Citations
163	Soluble L-selectin levels predict survival in sepsis. Intensive Care Medicine, 2002, 28, 1613-1618.	3.9	52
164	Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clinical Cancer Research, 2002, 8, 156-64.	3.2	107
165	Recent therapeutic advances in inflammatory bowel disease. IDrugs: the Investigational Drugs Journal, 2002, 5, 618-22.	0.7	0
166	The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Alimentary Pharmacology and Therapeutics, 2001, 15, 1699-1708.	1.9	179
167	Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut, 2001, 49, 42-46.	6.1	212
168	Impaired Sensitivity to Î²2 Integrin-Blocking in ICAM-1-Mediated Neutrophil Migration in Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 2001, 36, 621-629.	0.6	10
169	Comparative Studies of the Colonic In Situ Expression of Intercellular Adhesion Molecules (ICAM-1, -2,) Tj ETQq1 1 0.784314 rgBT /Ov American Journal of Surgical Pathology, 2000, 24, 1115-1124.	2.1	64
170	Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine. Alimentary Pharmacology and Therapeutics, 2000, 14, 1023-1031.	1.9	16
171	Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clinical and Experimental Immunology, 2000, 121, 242-247.	1.1	75
172	Systemic Inflammatory Responses during Laparoscopic and Open Inguinal Hernia Repair: A Randomised Prospective Study. The European Journal of Surgery, 2000, 166, 540-544.	1.0	46
173	Clinical Reviews. American Journal of Gastroenterology, 2000, 95, 359-367.	0.2	74
174	COLONIC EXPRESSION AND SYNTHESIS OF INTERLEUKIN 13 AND INTERLEUKIN 15 IN INFLAMMATORY BOWEL DISEASE. Cytokine, 2000, 12, 1531-1536.	1.4	65
175	Chemotactic properties of ICAM-1 and PECAM-1 on neutrophils in ulcerative colitis: Influence of prednisolone. Gastroenterology, 2000, 118, A354.	0.6	0
176	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology, 2000, 119, 1461-1472.	0.6	442
177	Established and emerging biological activity markers of inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 359-367.	0.2	145
178	Rectal Dialysate and Fecal Concentrations of Neutrophil Gelatinase-Associated Lipocalin, Interleukin-8, and Tumor Necrosis Factor-Î± in Ulcerative Colitis. American Journal of Gastroenterology, 1999, 94, 2923-2928.	0.2	100
179	Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis. Digestive Diseases and Sciences, 1999, 44, 415-423.	1.1	17
180	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-Î± in ulcerative colitis. American Journal of Gastroenterology, 1999, 94, 2923-2928.	0.2	74

#	Article	IF	Citations
181	Expression of E-selectin, sialyl Lewis X, and macrophage inflammatory protein-1alpha by colonic epithelial cells in ulcerative colitis. Digestive Diseases and Sciences, 1998, 43, 596-608.	1.1	38
182	Interleukin-15 and its role in chronic inflammatory diseases. Inflammation Research, 1998, 47, 285-289.	1.6	60
183	The Circulating Common Gamma Chain (CD132) in Inflammatory Bowel Disease. American Journal of Gastroenterology, 1998, 93, 323-328.	0.2	25
184	Circulating L-selectin levels and endothelial CD34 expression in inflammatory bowel disease. American Journal of Gastroenterology, 1998, 93, 1854-1859.	0.2	19
185	Intestinal Interleukin-8 Concentration and Gene Expression in Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 1997, 32, 1028-1034.	0.6	59
186	Expression of common gamma chain on peripheral blood mononuclear cells in Crohn's disease. Digestive Diseases and Sciences, 1997, 42, 372-377.	1.1	3
187	Increased hepatic urea synthesis in patients with active inflammatory bowel disease. Journal of Hepatology, 1996, 24, 587-593.	1.8	19
188	Changes in Extent of Ulcerative Colitis A Study on the Course and Prognostic Factors. Scandinavian Journal of Gastroenterology, 1996, 31, 260-266.	0.6	218
189	Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The immunological network: Novel approaches to the treatment of Crohn's disease. Expert Opinion on Investigational Drugs, 1996, 5, 555-564.	1.9	1
190	A simple filter-paper technique allows detection of mucosal cytokine levelsin vivo in ulcerative colitis. Digestive Diseases and Sciences, 1996, 41, 1775-1779.	1.1	8
191	Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Digestive Diseases and Sciences, 1996, 41, 1780-1785.	1.1	39
192	Involvement of interleukin-4 and -10 in inflammatory bowel disease. Digestive Diseases and Sciences, 1996, 41, 1786-1793.	1.1	90
193	LFA-1 subunit expression in ulcerative colitis patients. Digestive Diseases and Sciences, 1996, 41, 670-676.	1.1	16
194	Serum from NSAID-treated patients attenuates the capacity of rat leukocytes to synthesize leukotriene B4. Inflammation Research, 1996, 45, 31-34.	1.6	2
195	Interleukin-2 receptor Î± and Î² chain expression by circulating Î±Î² and Î³Î´ T cells in inflammatory bowel disease. Digestive Diseases and Sciences, 1995, 40, 291-295.	1.1	13
196	Adhesion Molecules in Inflammatory and Neoplastic Intestinal Diseases. Digestive Diseases, 1995, 13, 322-336.	0.8	10
197	Tolerability of interferon alphaâ€2b, a possible new treatment of active Crohn's disease. Alimentary Pharmacology and Therapeutics, 1995, 9, 75-79.	1.9	14
198	In vitroSuperoxide Production by Peripheral Neutrophils from Patients with Inflammatory Bowel Disease. Mediators of Inflammation, 1994, 3, 161-164.	1.4	3

#	Article	IF	Citations
199	Serum Concentration and Chemotactic Activity of E-selectin (CD62E) in Inflammatory Bowel Disease. Mediators of Inflammation, 1994, 3, 215-218.	1.4	14
200	Cytokines (Immunoinflammatory Hormones) and Their Natural Regulation in Inflammatory Bowel Disease (Crohnâ€™s Disease and Ulcerative Colitis): A Review. Digestive Diseases, 1994, 12, 290-304.	0.8	71
201	Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Digestive Diseases and Sciences, 1994, 39, 1918-1923.	1.1	59
202	Effect of 5-Aminosalicylic Acid and Analogous Substances on Superoxide Generation and Intracellular Free Calcium in Human Neutrophilic Granulocytes. Scandinavian Journal of Gastroenterology, 1993, 28, 527-532.	0.6	20
203	Soluble interleukin-2 receptors in ulcerative colitis. Mediators of Inflammation, 1993, 2, 115-118.	1.4	13
204	Cytokines in Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 1992, 27, 897-906.	0.6	58
205	Incidence and Prevalence of Crohn's Disease in the County of Copenhagen, 1962-87: A Sixfold Increase in Incidence. Scandinavian Journal of Gastroenterology, 1992, 27, 609-614.	0.6	282
206	Arachidonic acid and calcium metabolism in rnelittin stimulated neutrophils. Mediators of Inflammation, 1992, 1, 313-317.	1.4	6
207	Familial Occurrence of Inflammatory Bowel Disease. New England Journal of Medicine, 1991, 324, 84-88.	13.9	605
208	Involvement of oxygen-derived free radicals in the pathogenesis of chronic inflammatory bowel disease. Klinische Wochenschrift, 1991, 69, 995-1000.	0.6	21
209	Incidence and Prevalence of Ulcerative Colitis in Copenhagen County from 1962 to 1987. Scandinavian Journal of Gastroenterology, 1991, 26, 1247-1256.	0.6	252
210	Clinical Evidence Supporting the Radical Scavenger Mechanism of 5-Aminosalicylic Acid. Gastroenterology, 1990, 98, 1162-1169.	0.6	223
211	Recombinant human tumour necrosis factor increases cytosolic free calcium in murine fibroblasts and stimulates inositol phosphate formation in L-M and arachidonic acid release in 3T3 cells. Cellular Signalling, 1990, 2, 479-487.	1.7	18
212	Arachidonic Acid Metabolism in Neutrophil Granulocytes Obtained from Synovial Fluid in Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 1990, 19, 387-391.	0.6	4
213	Gastric Emptying and Subjective Symptoms of Nausea: Lack of Effects of a 5-Hydroxytryptamine-3 Antagonist Ondansetron on Gastric Emptying in Patients with Gastric Stasis Syndrome. Digestion, 1990, 46, 89-96.	1.2	43
214	Effects of antirheumatic drugs on endogenous arachidonate metabolism and chemotaxis in human neutrophil granulocytes. Agents and Actions, 1989, 26, 233-234.	0.7	3
215	Serum interferon activity in inflammatory bowel disease. Inflammation, 1988, 12, 169-179.	1.7	10
216	Concentrations of IgA, Secretory IgA, IgM, Secretory IgM, IgD, and IgG in the Upper Jejunum of Children Without Gastrointestinal Disorders. Journal of Pediatric Gastroenterology and Nutrition, 1988, 7, 867-871.	0.9	6

#	Article	IF	Citations
217	Activation of neutrophil Chemotaxis by leukotriene B4and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 605-611.	0.6	41
218	Enhanced capacity for release of leucotriene B4 by neutrophils in rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1987, 46, 501-505.	0.5	38
219	5-Aminosalicylic Acid in the Treatment of Crohn's Disease: A 16-Week Double-Blind, Placebo-Controlled, Multicentre Study with PentasaÂ®. Scandinavian Journal of Gastroenterology, 1987, 22, 877-883.	0.6	128
220	The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents and Actions, 1987, 21, 191-194.	0.7	90
221	Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. Journal of Medical Virology, 1987, 21, 39-47.	2.5	93
222	Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Digestive Diseases and Sciences, 1987, 32, 577-582.	1.1	87
223	5â€Aminosalicylic Acid in the Treatment of Inflammatory Bowel Disease. Acta Medica Scandinavica, 1987, 221, 227-242.	0.0	43
224	Activation of neutrophil Chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 605-611.	0.6	11
225	Prognostic factors in neuroblastomas treated in denmark from 1943 to 1980:A statistical estimate of prognosis based on 253 cases. Cancer, 1986, 58, 2726-2735.	2.0	42
226	Arachidonic acid metabolism in human neutrophils: Lack of effect of cyclosporine A. International Journal of Immunopharmacology, 1986, 8, 419-426.	1.1	23
227	Gastric emptying rate and small bowel transit time in patients with irritable bowel syndrome determined with99mTc-labeled pellets and scintigraphy. Digestive Diseases and Sciences, 1986, 31, 1287-1291.	1.1	41
228	Steady-State Kinetics of 5-Aminosalicylic Acid and Sulfapyridine during Sulfasalazine Prophylaxis in Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 1986, 21, 693-700.	0.6	51
229	Malignant Diseases and Mortality Rate. Scandinavian Journal of Gastroenterology, 1985, 20, 13-18.	0.6	77
230	Neuroblastomas treated at the four major child oncologic clinics in Denmark 1943â€“1980: An evaluation of 180 cases. Medical and Pediatric Oncology, 1985, 13, 180-186.	1.0	25
231	Rotavirus Antibodies in the Mother and Her Breast-Fed Infant. Journal of Pediatric Gastroenterology and Nutrition, 1985, 4, 414-420.	0.9	35
232	Calcium Absorption and Acceptance of Low-Lactose Milk Among Children with Primary Lactase Deficiency. Journal of Pediatric Gastroenterology and Nutrition, 1984, 3, 219-223.	0.9	23
233	Normal Cultivable Microflora in Upper Jejunal Fluid in Children Without Gastrointestinal Disorders. Journal of Pediatric Gastroenterology and Nutrition, 1984, 3, 683-686.	0.9	13
234	Pregnancy in Ulcerative Colitis. Scandinavian Journal of Gastroenterology, 1983, 18, 735-742.	0.6	288

#	Article	IF	Citations
235	Pediatric Tube System for Collection of Uncontaminated Jejunal Juice. Journal of Pediatric Gastroenterology and Nutrition, 1983, 2, 483-486.	0.9	1
236	Tube for Sampling of Uncontaminated Small-Bowel Juice. Scandinavian Journal of Gastroenterology, 1983, 18, 359-363.	0.6	8
237	Comparison of an Open and a Closed Tube System for Collection of Jejunal Juice. Scandinavian Journal of Gastroenterology, 1983, 18, 353-357.	0.6	12
238	Sulfasalazine Intolerance. Scandinavian Journal of Gastroenterology, 1982, 17, 389-393.	0.6	98
239	The Incidence of Anemia, Hypoproteinemia, and Edema in Infants as Presenting Symptoms of Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 1982, 1, 355-360.	0.9	32
240	ADRENOGENITAL SYNDROME AND CYSTIC FIBROSIS. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 339-341.	0.7	1
241	Anti-TNF-a Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease. Frontiers of Gastrointestinal Research, 0, , 206-213.	0.1	1